Breakthrough Discovery: How Liver Cancer Metabolism Can Be Disrupted Through Protein Acetylation

A novel study has revealed a sophisticated metabolic mechanism driving liver cancer progression, potentially opening new pathways for diagnosis and treatment of hepatocellular carcinoma (HCC). Scientists from the University of Science and Technology of China have demonstrated how acetylation of the pyruvate dehydrogenase complex component X (PDHX) protein fundamentally changes cancer cell metabolism.

The research focuses on a critical metabolic transformation where cancer cells modify their energy production through a process called aerobic glycolysis. By identifying how PDHX acetylation at lysine 488 disrupts the pyruvate dehydrogenase complex (PDC), researchers uncovered a significant mechanism that reroutes glucose metabolism and accelerates tumor growth.

Specifically, the study found that acetylation by the p300 enzyme impedes PDHX interactions with other metabolic proteins, reducing PDC activity. This disruption triggers a metabolic shift towards increased lactate production, which subsequently induces histone modifications that activate oncogenes responsible for tumor progression.

The implications of this research are substantial. PDHX acetylation levels were found to correlate directly with poor clinical outcomes in liver cancer patients. Moreover, inhibiting this acetylation or restoring PDC function demonstrated potential in suppressing tumor development, suggesting a promising therapeutic approach.

Researchers demonstrated that treatments like dichloroacetate (DCA), which can restore PDC function, were particularly effective against tumors with high PDHX acetylation levels. This finding suggests a potential personalized treatment strategy that targets specific metabolic characteristics of individual tumors.

Dr. Huafeng Zhang, the study's senior author, emphasized the significance of their discovery, noting that it represents a crucial advancement in understanding cancer metabolism. The research not only provides insights into liver cancer biology but also creates potential new pathways for targeted therapeutic development.

Future research will likely focus on developing inhibitors targeting the p300 acetyltransferase or exploring existing drugs that can restore PDC activity. These approaches could lead to more effective, precision-based treatments for liver cancer patients, potentially improving survival rates and patient outcomes.